Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/15/2862691/0/en/Pulmocide-Announces-Successful-Results-from-the-OPERA-S-Study-a-Phase-2-Safety-Study-with-Inhaled-Opelconazole.html
https://www.fiercebiotech.com/biotech/pulmocide-exits-opera-phase-2-evidence-antifungal-safety-and-efficacy
https://www.globenewswire.com//news-release/2023/10/16/2760577/0/en/Pulmocide-Announces-New-Clinical-Data-Confirming-Low-Potential-for-Drug-Drug-Interactions-with-Inhaled-Opelconazole.html
https://www.globenewswire.com/news-release/2023/06/08/2684591/0/en/Pulmocide-Announces-Expansion-of-Management-Team.html
https://www.globenewswire.com//news-release/2022/12/06/2568135/0/en/Pulmocide-Raises-52-Million-to-Fund-Additional-Late-Stage-Development-of-Opelconazole.html
https://www.globenewswire.com/news-release/2021/09/15/2297166/0/en/Pulmocide-s-lead-drug-candidate-opelconazole-PC945-granted-Orphan-Drug-Fast-Track-and-Qualified-Infectious-Disease-Product-Designations-by-US-FDA.html